StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals McKesson Corp. by Year

McKesson Corp. — Share of gross accounts receivable (%) (%)

Vertex Pharmaceuticals McKesson Corp.: 1,900.0% in FY2025, up 200.0 pts from a year earlier.

Latest, FY2025
1,900.0%
Period ended Dec 31, 2025
Change on a year earlier
+200.0 pts
1,700.0% in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-K Note (Significant Revenue & Receivable Concentrations).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedMcKesson Corp. — Share of gross accounts receivable (%) (%)Year on yearSource
FY2025Dec 31, 20251,900.0%+200.0 ptsForm 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 20241,700.0%-600.0 ptsForm 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 20232,300.0%+100.0 ptsForm 10-K (filed 2025-02-13) ↗
FY2022Dec 31, 20222,200.0%+100.0 ptsForm 10-K (filed 2024-02-15) ↗
FY2021Dec 31, 20212,100.0%+700.0 ptsForm 10-K (filed 2023-02-10) ↗
FY2020Dec 31, 20201,400.0%-800.0 ptsForm 10-K (filed 2022-02-09) ↗
FY2019Dec 31, 20192,200.0%+600.0 ptsForm 10-K (filed 2021-02-11) ↗
FY2018Dec 31, 20181,600.0%+600.0 ptsForm 10-K (filed 2020-02-13) ↗
FY2017Dec 31, 20171,000.0%–Form 10-K (filed 2019-02-13) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals McKesson Corp. (%), annual FY2017–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/conc-mckesson-ar

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.